文献速递主动脉疾病血液透析通路

EVAR、TEVAR与TAVR中动脉切开闭合装置的系统综述与Meta分析

Editor's Choice - Arteriotomy Closure Devices in EVAR, TEVAR, and TAVR: A Systematic Review and Meta-analysis of Randomised Clinical Trials and Cohort Studies.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2017-04-21

该研究系统检索2000至2016年文献,纳入17项研究共7889个血管入路点,比较动脉切开闭合装置(ACD)与外科切开(SCD)在EVAR、TEVAR和TAVR中的效果。ACD组伤口并发症更少,但假性动脉瘤更多,手术时长和住院时间未缩短,证据质量中等。

要点

  • ACD减少伤口裂开、血清肿和手术部位感染,但假性动脉瘤风险增加。
  • ACD未缩短手术时长或住院时间。
  • 在合适患者中,ACD用于股总动脉入路可考虑为安全。

核心结论

  • 在EVAR、TEVAR和TAVR中,ACD相比SCD减少伤口并发症数量,但手术时长和住院时间未减少。
  • 差异临床意义有限,证据质量中等,ACD在合适患者中可考虑安全。

研究设计与样本

  • 系统检索MEDLINE、Embase和Cochrane Library(2000-2016年),纳入比较ACD与SCD的随机对照试验和队列研究。
  • 共17项研究纳入Meta分析,描述7889个血管入路点;其中4项随机试验、2项前瞻性数据库研究、11项回顾性队列研究。

主要发现

  • ACD组术后血清肿更少(OR 0.15,95%CI 0.06-0.35)。
  • ACD组伤口裂开更少(OR 0.14,95%CI 0.03-0.78)。
  • ACD组手术部位感染更少(OR 0.38,95%CI 0.23-0.63)。
  • ACD组术后假性动脉瘤显著更常见(OR 3.83,95%CI 1.55-9.44)。
  • 17项研究中有5项报告ACD组手术时长和住院时间未减少;非参数分析显示两者无显著差异。

临床怎么用

  • 在EVAR、TEVAR和TAVR中,对于合适的患者,ACD可考虑用于股总动脉入路。
  • 需权衡ACD减少伤口并发症但增加假性动脉瘤风险,且不缩短手术时长或住院时间。

局限性

  • 证据质量中等,差异临床意义有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cardiac and vascular surgery benefit from percutaneous interventions. Arteriotomy closure devices (ACDs) enable minimally invasive access to the common femoral artery (CFA). The objective of this review was to assess the differences between ACDs and surgical cut down (SCD) of the CFA regarding the number of complications, duration of surgery (DOS), and hospital length of stay (HLOS). DESIGN: A systematic literature search with predefined search terms was performed using MEDLINE, Embase, and the Cochrane Library (2000-2016). All studies reporting on ACD and SCD for a puncture of the CFA of at least 12 French (Fr.) were assessed for eligibility. METHODS: Included were randomised controlled trials and cohort studies comparing both techniques. Patient characteristics, exclusion criteria, and conversion rates were evaluated. Complications, DOS, and HLOS were compared. MATERIALS: A total of 17 studies were included for meta-analysis, describing 7889 vascular access sites; four studies were randomised trials, two studies reported from a prospective database, and 11 studies reported retrospective cohorts. RESULTS: ACD was associated with fewer post-operative seromas (odds ratio [OR] 0.15, 95% confidence interval [CI] 0.06-0.35), less wound dehiscence (OR 0.14, 95% CI 0.03-0.78), and fewer surgical site infections (OR 0.38, 95% CI 0.23-0.63). Post-operative pseudoaneurysms were significantly more common in the ACD group (OR 3.83, 95% CI 1.55-9.44). In five of 17 studies, DOS and HLOS were not reduced in the ACD group. When all studies reporting a mean DOS and/or HLOS were compared in a non-parametric analysis, neither was significantly different. CONCLUSION: This meta-analysis favours ACD regarding the number of wound complications compared with SCD in endovascular aneurysm repair, thoracic endovascular aneurysm repair, and transcatheter aortic valve repair. Treatment duration (DOS and HLOS) was not reduced in ACD. The differences are of limited clinical significance and with this equivocal quality of evidence, the ACD may be considered safe for CFA access in suitable patients.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Vierhout BP, Pol RA, El Moumni M, et al. Editor's Choice - Arteriotomy Closure Devices in EVAR, TEVAR, and TAVR: A Systematic Review and Meta-analysis of Randomised Clinical Trials and Cohort Studies. Eur J Vasc Endovasc Surg. 2017. PMID: 28438400. doi:10.1016/j.ejvs.2017.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。